Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study.

Abstract

This study aimed to compare the outcomes of combined hepatic resection (HR) plus intraoperative radiofrequency ablation (RFA) and transarterial embolization (TAE) for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) in case-controlled patient groups using the propensity score. A total of 179 patients with multifocal HCC treated with HR plus RFA (n=26) or TAE(n=153) were retrospectively studied. All patients were classified as BCLC stage B and Child-Pugh class A. Analyses were performed over all participants as well as for propensity score-matched (1:3) patients to adjust for baseline differences. Cumulative overall survival (OS) and time to progression (TTP) were compared between the two groups using the Kaplan-Meier method, and independent predictors were identified by multivariate Cox regression analysis. Patients treated with HR plus RFA had better OS and longer TTP than those with TAE (p=0.011 and p<0.001, respectively). Multivariate Cox regression analysis showed that combined therapy (hazard ratio 0.31; 95% confidence interval (CI), 0.12-0.78; p=0.013), BCLC substage B2 (hazard ratio 1.82; 95% CI, 1.13-2.92; p=0.013) and alpha-fetoprotein≥400ng/ml (hazard ratio 1.85; 95% CI, 1.12-3.05; p=0.016) were independent factors associated with OS. After propensity score matching, combined therapy was the significant factor associated with OS and TTP by univariate and multivariate analyses. Combined HR plus RFA may provide survival advantage compared to TAE in patients with BCLC stage B HCC.